Drugs / vaccinia immune globulin
vaccinia immune globulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00081835 | Apr 2004 → Aug 2007 | vaccinia | National Eye Institute (NEI) | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vaccinia immune globulin | “an experimental treatment called NP-016 vaccinia immune globulin can reduce corneal scarring” NCT00081835 ↗ |
| Known as | Human vaccinia immune globulin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108699 ↗ |
| Known as | NP-016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00081835 ↗ |
| Known as | Vaccine Immune Globulin (IV-VIG) | “NP-016 Vaccine Immune Globulin (IV-VIG)” NCT00081835 ↗ |
| Known as | Vaccinia Immune Globulin Intravenous (Human) | “Vaccinia Immune Globulin Intravenous (Human) (VIGIV, formerly known as NP-016)” NCT00081835 ↗ |
| Known as | Vaccinia immunoglobulin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108699 ↗ |
| Known as | Vaccinia immunoglobulins | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108699 ↗ |
| Known as | VIG | “NP-016 Vaccine Immune Globulin (IV-VIG)” NCT00081835 ↗ |
| Known as | VIGIV | “Vaccinia Immune Globulin Intravenous (Human) (VIGIV, formerly known as NP-016)” NCT00081835 ↗ |
| Modality | Protein / enzyme biologic | “Vaccinia Immune Globulin Intravenous (Human)” NCT00081835 ↗ |
| Route | Intravenous | “intravenous (through a vein) infusions of either VIG or placebo” NCT00081835 ↗ |